Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer-Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and In Vivo Biodistribution
The objective of the present study was to develop long-acting efavirenz (Efa)-enfuvirtide (Enf) Co-loaded polymer-lipid hybrid nanoparticles (PLN) with improved intracellular delivery to target T-cells and macrophage cells located in multiple human immunodeficiency virus sanctuaries. The Box-Behnken...
Saved in:
| Published in: | Molecular pharmaceutics Vol. 17; no. 10; p. 3990 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
05.10.2020
|
| ISSN: | 1543-8392, 1543-8392 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The objective of the present study was to develop long-acting efavirenz (Efa)-enfuvirtide (Enf) Co-loaded polymer-lipid hybrid nanoparticles (PLN) with improved intracellular delivery to target T-cells and macrophage cells located in multiple human immunodeficiency virus sanctuaries. The Box-Behnken design was utilized to optimize three high-risk factors, namely, Efa amount, sonication time for primary emulsion, and sonication time for aqueous nanodispersion obtained from preliminary studies. Lyophilized Efa-Enf Co-loaded PLN using trehalose elicited spherical morphology, drug amorphization on incorporation, and absence of drug-excipient interaction. In vitro release studies revealed an sustained release of both the drugs from PLN with the differential release profile. Efa-Enf Co-loaded PLN exhibited low hemolytic, platelet and leukocyte aggregation as well as low cytotoxicity in Jurkat E6.1 T-cells and U937 macrophage cells. Circular dichroism spectra confirmed the presence of an α-helix form of Enf after encapsulation in PLN. Coumarin-6-loaded PLN exhibited enhanced cellular uptake in Jurkat E6.1 T-cells and U937 macrophage cells in comparison to free coumarin-6, as evidenced by fluorescence microscopy and flow cytometry. In vivo biodistribution studies after intravenous administration of near-infrared dye-loaded PLN (surrogate for Efa-Enf PLN) revealed non-uniform distribution within 2 h in the order of spleen ≥ liver > lymph node > thymus > lungs > female reproductive tract (FRT) > heart > kidneys > brain. However, subcutaneous administration caused non-uniform biodistribution after 3 days, eliciting a long-acting slow release from the injection site depot until day 5 in the infection-spread site (lymph nodes and FRT), reservoir sites (liver and spleen) and the difficult-to-access site (brain). Furthermore, it presents a vital illustration of the available tissue-specific drug concentration prediction from simulated surrogate PLN.The objective of the present study was to develop long-acting efavirenz (Efa)-enfuvirtide (Enf) Co-loaded polymer-lipid hybrid nanoparticles (PLN) with improved intracellular delivery to target T-cells and macrophage cells located in multiple human immunodeficiency virus sanctuaries. The Box-Behnken design was utilized to optimize three high-risk factors, namely, Efa amount, sonication time for primary emulsion, and sonication time for aqueous nanodispersion obtained from preliminary studies. Lyophilized Efa-Enf Co-loaded PLN using trehalose elicited spherical morphology, drug amorphization on incorporation, and absence of drug-excipient interaction. In vitro release studies revealed an sustained release of both the drugs from PLN with the differential release profile. Efa-Enf Co-loaded PLN exhibited low hemolytic, platelet and leukocyte aggregation as well as low cytotoxicity in Jurkat E6.1 T-cells and U937 macrophage cells. Circular dichroism spectra confirmed the presence of an α-helix form of Enf after encapsulation in PLN. Coumarin-6-loaded PLN exhibited enhanced cellular uptake in Jurkat E6.1 T-cells and U937 macrophage cells in comparison to free coumarin-6, as evidenced by fluorescence microscopy and flow cytometry. In vivo biodistribution studies after intravenous administration of near-infrared dye-loaded PLN (surrogate for Efa-Enf PLN) revealed non-uniform distribution within 2 h in the order of spleen ≥ liver > lymph node > thymus > lungs > female reproductive tract (FRT) > heart > kidneys > brain. However, subcutaneous administration caused non-uniform biodistribution after 3 days, eliciting a long-acting slow release from the injection site depot until day 5 in the infection-spread site (lymph nodes and FRT), reservoir sites (liver and spleen) and the difficult-to-access site (brain). Furthermore, it presents a vital illustration of the available tissue-specific drug concentration prediction from simulated surrogate PLN. |
|---|---|
| AbstractList | The objective of the present study was to develop long-acting efavirenz (Efa)-enfuvirtide (Enf) Co-loaded polymer-lipid hybrid nanoparticles (PLN) with improved intracellular delivery to target T-cells and macrophage cells located in multiple human immunodeficiency virus sanctuaries. The Box-Behnken design was utilized to optimize three high-risk factors, namely, Efa amount, sonication time for primary emulsion, and sonication time for aqueous nanodispersion obtained from preliminary studies. Lyophilized Efa-Enf Co-loaded PLN using trehalose elicited spherical morphology, drug amorphization on incorporation, and absence of drug-excipient interaction. In vitro release studies revealed an sustained release of both the drugs from PLN with the differential release profile. Efa-Enf Co-loaded PLN exhibited low hemolytic, platelet and leukocyte aggregation as well as low cytotoxicity in Jurkat E6.1 T-cells and U937 macrophage cells. Circular dichroism spectra confirmed the presence of an α-helix form of Enf after encapsulation in PLN. Coumarin-6-loaded PLN exhibited enhanced cellular uptake in Jurkat E6.1 T-cells and U937 macrophage cells in comparison to free coumarin-6, as evidenced by fluorescence microscopy and flow cytometry. In vivo biodistribution studies after intravenous administration of near-infrared dye-loaded PLN (surrogate for Efa-Enf PLN) revealed non-uniform distribution within 2 h in the order of spleen ≥ liver > lymph node > thymus > lungs > female reproductive tract (FRT) > heart > kidneys > brain. However, subcutaneous administration caused non-uniform biodistribution after 3 days, eliciting a long-acting slow release from the injection site depot until day 5 in the infection-spread site (lymph nodes and FRT), reservoir sites (liver and spleen) and the difficult-to-access site (brain). Furthermore, it presents a vital illustration of the available tissue-specific drug concentration prediction from simulated surrogate PLN.The objective of the present study was to develop long-acting efavirenz (Efa)-enfuvirtide (Enf) Co-loaded polymer-lipid hybrid nanoparticles (PLN) with improved intracellular delivery to target T-cells and macrophage cells located in multiple human immunodeficiency virus sanctuaries. The Box-Behnken design was utilized to optimize three high-risk factors, namely, Efa amount, sonication time for primary emulsion, and sonication time for aqueous nanodispersion obtained from preliminary studies. Lyophilized Efa-Enf Co-loaded PLN using trehalose elicited spherical morphology, drug amorphization on incorporation, and absence of drug-excipient interaction. In vitro release studies revealed an sustained release of both the drugs from PLN with the differential release profile. Efa-Enf Co-loaded PLN exhibited low hemolytic, platelet and leukocyte aggregation as well as low cytotoxicity in Jurkat E6.1 T-cells and U937 macrophage cells. Circular dichroism spectra confirmed the presence of an α-helix form of Enf after encapsulation in PLN. Coumarin-6-loaded PLN exhibited enhanced cellular uptake in Jurkat E6.1 T-cells and U937 macrophage cells in comparison to free coumarin-6, as evidenced by fluorescence microscopy and flow cytometry. In vivo biodistribution studies after intravenous administration of near-infrared dye-loaded PLN (surrogate for Efa-Enf PLN) revealed non-uniform distribution within 2 h in the order of spleen ≥ liver > lymph node > thymus > lungs > female reproductive tract (FRT) > heart > kidneys > brain. However, subcutaneous administration caused non-uniform biodistribution after 3 days, eliciting a long-acting slow release from the injection site depot until day 5 in the infection-spread site (lymph nodes and FRT), reservoir sites (liver and spleen) and the difficult-to-access site (brain). Furthermore, it presents a vital illustration of the available tissue-specific drug concentration prediction from simulated surrogate PLN. |
| Author | Dighe, Vikas D Jirwankar, Yugandhara B Jindal, Anil B Surve, Dhanashree H |
| Author_xml | – sequence: 1 givenname: Dhanashree H surname: Surve fullname: Surve, Dhanashree H – sequence: 2 givenname: Yugandhara B surname: Jirwankar fullname: Jirwankar, Yugandhara B – sequence: 3 givenname: Vikas D surname: Dighe fullname: Dighe, Vikas D – sequence: 4 givenname: Anil B surname: Jindal fullname: Jindal, Anil B |
| BookMark | eNpNjstOwzAQRS0EEs9_MDsWpPiVJmEHVQuVKkDisa2mzqQYHDvYTiX4J_6R8FiwundGc8-dfbLtvENCjjkbcSb4Geg4ar3tniG0oLFPI6YZKwq5RfZ4rmRWykps__O7ZD_GF8aEyoXcI58L79bZhU7Grem0gY0J6D4ouJpez58yTmd9NN7RuXs2K5N8oHfYJVMjnfjMeqixpnfevrcYsoXpzBB7X4VBbsD5DkIy2mI8p_cJkonDBJbeDoDWfAwL707pBK3tLQT62CV4xdOf7rmjT2bj6aXx9RALZtV_Xx-SnQZsxKM_PSCPs-nD5Dpb3F7NJxeLDKRiKask55Uq6jEy2TCW57zESnOFuhAgeKnGijGNFUDFSlClHueyaeq8FIyNoajFATn55XbBv_UY07I1UQ-PgkPfx6VQcmCWIufiC4dLens |
| CitedBy_id | crossref_primary_10_1038_s41467_024_55544_9 crossref_primary_10_1038_s41467_024_53396_x crossref_primary_10_3390_v16091484 crossref_primary_10_3390_vaccines9090958 crossref_primary_10_1007_s00210_025_04169_w crossref_primary_10_1007_s44174_025_00437_8 crossref_primary_10_1016_j_jconrel_2025_113954 crossref_primary_10_3390_v15101992 crossref_primary_10_1016_j_biopha_2021_112249 crossref_primary_10_1016_j_addr_2023_114901 crossref_primary_10_1016_j_ijpharm_2021_120820 crossref_primary_10_3389_fphar_2023_1294966 crossref_primary_10_1016_j_addr_2023_114862 crossref_primary_10_1021_acsami_5c00499 crossref_primary_10_1097_COH_0000000000000688 crossref_primary_10_1016_j_molliq_2022_118724 crossref_primary_10_1016_j_ejps_2021_106024 crossref_primary_10_1016_j_jddst_2024_105589 |
| ContentType | Journal Article |
| DBID | 7X8 |
| DOI | 10.1021/acs.molpharmaceut.0c00773 |
| DatabaseName | MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1543-8392 |
| GroupedDBID | --- -~X 123 4.4 53G 55A 5VS 7X8 7~N AABXI ABBLG ABJNI ABLBI ABMVS ABQRX ABUCX ACGFS ACS ADHLV AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CS3 CUPRZ DU5 EBS ED~ F5P GGK GNL H~9 IH9 JG~ P2P RNS ROL UI2 VF5 VG9 W1F |
| ID | FETCH-LOGICAL-a340t-9311947d6e03f005518e9c14ec72a21846400ce9aa908a48c653ffd582006a7d2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 17 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000580389300028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1543-8392 |
| IngestDate | Thu Jul 10 23:32:21 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a340t-9311947d6e03f005518e9c14ec72a21846400ce9aa908a48c653ffd582006a7d2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PQID | 2435188251 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2435188251 |
| PublicationCentury | 2000 |
| PublicationDate | 20201005 |
| PublicationDateYYYYMMDD | 2020-10-05 |
| PublicationDate_xml | – month: 10 year: 2020 text: 20201005 day: 05 |
| PublicationDecade | 2020 |
| PublicationTitle | Molecular pharmaceutics |
| PublicationYear | 2020 |
| SSID | ssj0024523 |
| Score | 2.3919654 |
| Snippet | The objective of the present study was to develop long-acting efavirenz (Efa)-enfuvirtide (Enf) Co-loaded polymer-lipid hybrid nanoparticles (PLN) with... |
| SourceID | proquest |
| SourceType | Aggregation Database |
| StartPage | 3990 |
| Title | Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer-Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and In Vivo Biodistribution |
| URI | https://www.proquest.com/docview/2435188251 |
| Volume | 17 |
| WOSCitedRecordID | wos000580389300028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF5BixCXlqd4FDSVUE_Z1utdxzYXVKJGjYSKD22VWzX7KhHJbknaSOE_8R_ZcVzlwAWJux8j7_jbmdmZ72Pso3ZOKu0zrqzzXKWAgmMuFReur40xWqJWrdhEeXZWjcd10xXcFl1b5T0mtkBto6Ea-VGe9nVR0aDl55ufnFSj6HS1k9B4yLZlCmXIq8txteHaK1p5txQlSE6BwGO2vyYrEEdoFoezSOOsXeH4MDNEbSP_wuR2oxnu_q-JT9lOF2LC8donnrEHLjxnB83ahlUPzjcjV4seHECzYa9evWC_v8ZwzY8NtUPDicdlwsTwCzBYOB1dcgHDOyqwwSh8n-gEB3NoqDHGOhhEPo1onYUmTlczN-ckjJ1uW9FUGCQcTwl614f3CSjKbUmik6nf0gNm3UBoDwZuOqXmWLi4ucUfrte-exTgcrKM8GUSLXH9djJdL9nF8OR8cMo7TQeOUmW3vJZC1Kq0fZdJTwRgonK1EcqZMkdKN_sJVIyrEeusQlWZfiG9t0VFpQ8sbf6KbYUY3GsGCWoKRK0zL61yQqPEDFVRGF_4zFfmDdu_X6ar9M_QQQgGF-8WV5uFevsP17xjT3JKstuugT227RMuuPfskVmmzzT_0LrcHxXg5dI |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-Acting+Efavirenz+and+HIV-1+Fusion+Inhibitor+Peptide+Co-loaded+Polymer-Lipid+Hybrid+Nanoparticles%3A+Statistical+Optimization%2C+Cellular+Uptake%2C+and+In+Vivo+Biodistribution&rft.jtitle=Molecular+pharmaceutics&rft.au=Surve%2C+Dhanashree+H&rft.au=Jirwankar%2C+Yugandhara+B&rft.au=Dighe%2C+Vikas+D&rft.au=Jindal%2C+Anil+B&rft.date=2020-10-05&rft.issn=1543-8392&rft.eissn=1543-8392&rft.volume=17&rft.issue=10&rft.spage=3990&rft_id=info:doi/10.1021%2Facs.molpharmaceut.0c00773&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8392&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8392&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8392&client=summon |